Mantle cell lymphoma diagnostic study of choice

	Mantle cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mantle cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mantle cell lymphoma diagnostic study of choice On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mantle cell lymphoma diagnostic study of choice All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mantle cell lymphoma diagnostic study of choice
on Mantle cell lymphoma diagnostic study of choice
Mantle cell lymphoma diagnostic study of choice in the news
Blogs on Mantle cell lymphoma diagnostic study of choice
Directions to Hospitals Treating Mantle cell lymphoma
Risk calculators and risk factors for Mantle cell lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.

CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 typically are negative.
cyclin D1 is positive in 95% of cases
SOX11 expression may be useful if cyclin D1 is negative